期刊文献+

多参数流式细胞术在AML1/ETO阳性急性髓系白血病诊断中的应用研究 被引量:7

The application value of multiparameter flow cytometry in the diagnosis of acute myeloid leukemia with AML1/ETO
下载PDF
导出
摘要 目的本研究旨在探讨多参数流式细胞术(multiparameter flow cytometry,MFCM)在AML1/ETO融合基因阳性的急性髓系白血病(AML)诊断中的应用价值以及分析AML1/ETO融合基因阳性患者的骨髓细胞免疫表型,为病人早期诊断、分型和预后分层提供依据。方法将细胞遗传学或分子遗传学检查到AML1/ETO融合基因阳性作为金标准,筛选南昌大学第一附属医院2010年1月-2018年1月期间收治初诊AML1/ETO阳性AML患者44例,阴性患者44例,收集所有患者实验室信息(主要包括骨髓细胞形态学,多参数流式细胞术,细胞遗传学或分子遗传学检测结果)。采用四格表分别对骨髓细胞形态学和流式细胞术两种方法诊断AML1/ETO融合基因结果真实性和可靠性进行评价,比较骨髓细胞形态学、流式细胞术检查的诊断效能指标,探讨多参数流式细胞术在AML1/ETO融合基因相关的AML早期诊断中的应用价值并分析AML1/ETO阳性AML的免疫表型特点。结果 AML1/ETO阳性患者均表达CD117、CD34、CD33以及HLA-DR(阳性率100.00%),43例表达CD13(阳性率97.73%),42例表达CD19(阳性率95.45%)。CD117、CD34、HLA-DR以及CD19共表达的阳性率高达95.45%,而在44例AML1/ETO阴性患者中,均无此表型特点。多参数流式细胞术检测的灵敏度(81.82%vs25.00%),符合率(88.64%vs62.50%)以及阴性预测值(84.00%vs57.14%)明显高于形态学,漏诊率(18.18%vs75.00%)明显低于形态学,特异度(95.50%vs100%)略低于形态学,综合诊断效能明显优于形态学。结论多参数流式细胞术在AML1/ETO融合基因阳性AML的诊断中具有重要的应用价值,CD117、CD34、HLA-DR以及CD19的共表达是AML1/ETO融合基因阳性AML独特的免疫表型。 Objective To investigate the application value of multiparameter flow cytometry in acute myeloid leukemia with AML1/ETO and its immunophenotypic analysis,providing the basis for the early diagnosis,classification and prognosis stratification of patients.Methods Regarding cytogenetic or molecular genetics examination for AML1/ETO fusion gene as the golden standard,44 AML1/ETO positive AML patients and 44 AML1/ETO negative patients had been collected from the First Affiliated Hospital of Nanchang University in January 2010-January 2018.All of the patients’ lab information(including bone marrow cell morphology,multiparameter flow cytometry,the testing results of cytogenetics and molecular genetics) was recorded.Use four grid table to respectively evaluate authenticity and reliability of bone marrow cell morphology and flow cytometry diagnosing AML1/ETO fusion gene and then compare the diagnosis efficiency indexes of the two methods.Finally,discuss the application value of multiparameter flow cytometry in the early diagnosis of acute myeloid leukemia with AML1/ETO and its immunophenotypic?characteristics.Results All the AML1/ETO positive patients expressed CD117,CD34,CD33 and HLA-DR,43 patients expressed CD13(positive rate was 97.73%),and 42 patients(95.45%) expressed CD19.The co-expression rate of CD117,CD34,HLA-DR and CD19 was 95.45%,while none of the 44 AML1/ETO negative patients had this phenotypic feature.Multiparameter flow cytometry detection sensitivity(81.82%vs25.00%),coincidence rate(88.64%vs62.50%) and negative predictive value(84.00%vs57.14%)were significantly higher than bone marrow cell morphology.The rate of missed diagnosis(18.18%vs75.00%) was significantly lower than morphology,the specificity(95.50%vs100%) was slightly lower than morphology,and the comprehensive diagnostic efficiency was obviously better than morphology.Conclusion Multiparameter flow cytometry has important application value in the diagnosis of AML1/ETO fusion gene positive AML,and the co-expression of CD117,CD34,HLA-DR and CD19 is a unique immunophenotype of AML1/ETO fusion gene positive AML.
作者 江梅 郭海燕 聂益军 吕小林 万腊根 张长林 JIANG Mei;GUO Haiyan;NIE Yijun;LV Xiaolin;WAN Lagen;ZHANG Zhanglin(Department of Laboratorial Examination,The First Affiliated Hospital of Nanchang University,Nanchang 330006,China;Department of Pathology,The First Affiliated Hospital of Nanchang University,Nanchang 330006,China)
出处 《实验与检验医学》 CAS 2020年第1期9-12,35,共5页 Experimental and Laboratory Medicine
基金 江西省应用研究培育计划项目(编号:20181BBG78057) 江西省卫生计生委科技计划项目(编号:20165168) 江西省教育厅科学技术研究项目(编号:GJJ150127)
关键词 AML1/ETO 急性髓系白血病 多参数流式细胞术 应用价值 免疫表型 AML1/ETO Acute myeloid leukemia Multiparameter flow cytometry Application value Immunophenotype
  • 相关文献

参考文献3

二级参考文献14

  • 1汤美华,周宇,沈德诚,卞寿庚,钱林生,王琦,王志澄,陈璋.从AML细胞表面标记特点看AML、ALL鉴别时髓系单抗的选择[J].中华血液学杂志,1994,15(9):466-468. 被引量:12
  • 2肖志坚,郝玉书,李建波,冯宝章,徐丽娟,李幼升,汤美华,王建祥.t(8;21)急性髓细胞白血病──30例临床和实验室分析[J].中华血液学杂志,1995,16(4):190-192. 被引量:8
  • 3[1]Kita K,Nakase K,Miwa H,et al.Phenotypical characteristic of acute myelocytic leukemia associated with the t(8;21)(q22;q22) chromosomal abnormality;frequent expression of immature B-cell antigen CD19 together with stem cell antigen CD34.Blood,1992,80:470-477.
  • 4[2]Hurwitz CA,Raimodi SC,Head D,et al.Distinctive immunophenothic features of t(8;21)(q22;q22) acute myeloblastic leukemia in children.Blood,1992,80:3182-3188.
  • 5[3]Fourth International workshop on chromosome in leukemia 1982.Cancer Genet Cytogenet,1984,11:265-275.
  • 6[4]Felicetto F,Rosa N,Mario A,et al.Immunophenotypic analysis enables the correct prediction of t(8;21) in acute myeloid leukemia.Br J Haematol,1998,102:444-448.
  • 7[5]Solary E,Casasnovas QO,Canpos L,et al.Surface markers in adult acute myeloblastic leukemia:correction of CD19+,CD34+ and CD14+/DR-phenotypes with shorters survival.Group d'Etude Immunological des leucemies (GEIL).Leukemia,1992,6:393-398.
  • 8[6]Ball ED,Davis RB,Griffin JD,et al.Prognostic Value of lymphocytic surface markers in acute myeloid leukemia.Blood,1991,77:2222-2250.
  • 9[7]Porwit-MacDonald A,Janossy G,Ivory K,et al.Leukemia associatea changesidentified by quantitative flow cytometry.IV,CD34 overexpression in acute myelogenous Leukemia M2 with t(8;21).Blood,1996,87:1162-1172.
  • 10张之南,血液病诊断及疗效标准,1991年

共引文献24

同被引文献60

引证文献7

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部